Investments in Subsidiary Company by way of subscription towards Rights Issue
As filed · SMS Pharmaceuticals Limited has informed the Exchange about Investments in Subsidiary Company by way of subscription towards Rights Issue
What happened
FactSMSPHARMA has increased its holding in its subsidiary, SMS Peptides Private Limited, from 99.98% to 99.99% of the equity share capital. The company has provided the required disclosure under Schedule III of the Listing Regulations, which is included as Annexure-1 to the filing.
Why it matters
CapitSignal interpretationExisting holders can maintain their stake only by putting in more money; those who do not subscribe are diluted.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
RevisedOur revenue reached ₹783 crore, marking a 10% increase over the previous year, supported by steady demand across our therapeutic portfolio.
Anti-inflammatory products, led by ibuprofen, grew 22% year-on-year to ₹148 crore.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Rights ratio and issue price
- Record date and subscription window
- Promoter intention to subscribe
- Aim to add 8-10 products in the next 12-18 months in existing and new therapeutic areas (management committed by H1 FY27)
- Looking ahead, we are building a robust pipeline of high-potential molecules. (management committed by H1 FY27)
Evidence
- SMS Pharmaceuticals Limited has informed the Exchange about Investments in Subsidiary Company by way of subscription towards Rights Issue(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · FY25
- Earlier statement · FY25
How CapitSignal classified this
- Reasoning:
- RIGHTS_ISSUE base 64; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%